IMNM
ImmunomeCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
The strongest update since the prior baseline is real primary-source confirmation that varegacestat has moved from planned filing to submitted NDA status on April 29, 2026, with ASCO oral data close behind. If investors gain confidence that the FDA review proceeds normally and the detailed RINGSIDE presentation supports the topline profile, IMNM can still rerate despite the negative deterministic prior.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +11.9.
What can break
As of May 8, 2026, Immunome's investor-relations news page showed releases through May 5, 2026 but no Q1 2026 financial-results release, leaving the scheduled post-earnings follow-up with limited fresh operating disclosure. [#IR-NEWS-2026-05-08]
Momentum
84
Value
41
Sentiment
39
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $21.00 · Bull $30.00 · Bear $14.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $35.77
Why
Momentum84 · Δ7d +11.9
Value41 · Δ7d -0.0
Sentiment39 · Δ7d -1.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
84
26% active weight
Current posture
7d trendFlat
Δ7d
+11.9
Δ21d
+67.3
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
39
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.3
Δ21d
-8.6
Why this grade
Composite grade C. Momentum 83.7 / Value 41.1 / Sentiment 39.2
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$2.58B
Beta
2.33
Shares Out
113.25M
P/E (TTM) · Derived
-9.4
P/S (TTM)
224.68
P/FCF (TTM) · Derived
-10.57
Rev YoY
-100.0%
EPS YoY
-9.2%
Gross Margin
+25.7%
Op Margin
-2419.9%
Net Debt
-$649.63M
Current Ratio
21.68
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology